{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T14:51:51Z","timestamp":1785595911870,"version":"3.56.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:00:00Z","timestamp":1627948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:00:00Z","timestamp":1627948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00384-021-04002-9","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T23:05:17Z","timestamp":1628031917000},"page":"2621-2627","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pre-emptive oral clarithromycin reduces the skin toxicity of panitumumab treatment for metastatic colorectal cancer"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4086-4984","authenticated-orcid":false,"given":"Ken","family":"Nakata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamichi","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Saso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Noura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyasu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taroh","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunekazu","family":"Mizushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,3]]},"reference":[{"key":"4002_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1970","author":"ME Lacouture","year":"2006","unstructured":"Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. https:\/\/doi.org\/10.1038\/nrc1970","journal-title":"Nat Rev Cancer"},{"key":"4002_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.010","author":"ALC Agero","year":"2006","unstructured":"Agero ALC, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC (2006) Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2005.10.010","journal-title":"J Am Acad Dermatol"},{"key":"4002_CR3","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-610","author":"TJ Lynch","year":"2007","unstructured":"Lynch TJ, Kim ES, Eaby B, Garey J, West DP, Lacouture ME (2007) Epidermal growth factor receptor inhibitor\u2013associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. https:\/\/doi.org\/10.1634\/theoncologist.12-5-610","journal-title":"Oncologist"},{"key":"4002_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/734249","author":"K Chanprapaph","year":"2014","unstructured":"Chanprapaph K, Vachiramon V, Rattanakaemakorn P (2014) Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management. Dermatol Res Pract. https:\/\/doi.org\/10.1155\/2014\/734249","journal-title":"Dermatol Res Pract"},{"key":"4002_CR5","doi-asserted-by":"publisher","unstructured":"Lacouture ME\u00a0et al (2011)\u00a0\u201cClinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities,\u201d Support Care Cancer 19(8):1079\u20131095.\u00a0https:\/\/doi.org\/10.1007\/s00520-011-1197-6","DOI":"10.1007\/s00520-011-1197-6"},{"key":"4002_CR6","doi-asserted-by":"publisher","unstructured":"White KJ, Roydhouse JK, Scott K (2011)\u00a0\u201cPsychosocial impact of cutaneous toxicities associated with epidermal growth factor receptor-inhibitor treatment,\u201d Clin J Oncol Nurs 15(1).\u00a0https:\/\/doi.org\/10.1188\/11.CJON.88-96","DOI":"10.1188\/11.CJON.88-96"},{"key":"4002_CR7","doi-asserted-by":"publisher","unstructured":"Naughton MJ\u00a0et al (2013)\u00a0\u201cQuality of life (QOL) and toxicity among patients in CALGB 80405.,\u201d J Clin Oncol.\u00a0https:\/\/doi.org\/10.1200\/jco.2013.31.15_suppl.3611","DOI":"10.1200\/jco.2013.31.15_suppl.3611"},{"issue":"31","key":"4002_CR8","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","volume":"28","author":"M Peeters","year":"2010","unstructured":"Peeters M et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28(31):4706\u20134713. https:\/\/doi.org\/10.1200\/JCO.2009.27.6055","journal-title":"J Clin Oncol"},{"issue":"1","key":"4002_CR9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/ijc.27654","volume":"132","author":"S Stintzing","year":"2013","unstructured":"Stintzing S et al (2013) Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the German AIO CRC Stu. Int J Cancer 132(1):236\u2013245. https:\/\/doi.org\/10.1002\/ijc.27654","journal-title":"Int J Cancer"},{"key":"4002_CR10","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200809050-00002","author":"M Duvic","year":"2008","unstructured":"Duvic M (2008) EGFR inhibitor-associated acneiform folliculitis: assessment and management. Am J Clin Dermatol. https:\/\/doi.org\/10.2165\/00128071-200809050-00002","journal-title":"Am J Clin Dermatol"},{"key":"4002_CR11","doi-asserted-by":"publisher","DOI":"10.1159\/000112795","author":"SL Boone","year":"2008","unstructured":"Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME (2008) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology. https:\/\/doi.org\/10.1159\/000112795","journal-title":"Oncology"},{"issue":"8","key":"4002_CR12","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","volume":"28","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME et al (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28(8):1351\u20131357. https:\/\/doi.org\/10.1200\/JCO.2008.21.7828","journal-title":"J Clin Oncol"},{"issue":"4","key":"4002_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2217\/fon.14.251","volume":"11","author":"Y Kobayashi","year":"2015","unstructured":"Kobayashi Y et al (2015) Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. Futur Oncol 11(4):617\u2013627. https:\/\/doi.org\/10.2217\/fon.14.251","journal-title":"Futur Oncol"},{"issue":"6","key":"4002_CR14","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/bjd.14756","volume":"175","author":"F Petrelli","year":"2016","unstructured":"Petrelli F et al (2016) Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis. Br J Dermatol 175(6):1166\u20131174. https:\/\/doi.org\/10.1111\/bjd.14756","journal-title":"Br J Dermatol"},{"issue":"11","key":"4002_CR15","first-page":"6175","volume":"35","author":"M Yamada","year":"2015","unstructured":"Yamada M et al (2015) Prophylactic effect of oral minocycline in combination with topical steroid and skin care against panitumumab-induced acneiform rash in metastatic colorectal cancer patients. Anticancer Res 35(11):6175\u20136181","journal-title":"Anticancer Res"},{"issue":"13","key":"4002_CR16","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","volume":"25","author":"E Van Cutsem","year":"2007","unstructured":"Van Cutsem E et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer. J Clin Oncol 25(13):1658\u20131664. https:\/\/doi.org\/10.1200\/JCO.2006.08.1620","journal-title":"J Clin Oncol"},{"issue":"31","key":"4002_CR17","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","volume":"28","author":"JY Douillard","year":"2010","unstructured":"Douillard JY et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28(31):4697\u20134705. https:\/\/doi.org\/10.1200\/JCO.2009.27.4860","journal-title":"J Clin Oncol"},{"key":"4002_CR18","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M241","author":"HT Eng","year":"2009","unstructured":"Eng HT, Chan A (2009) Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann Pharmacother. https:\/\/doi.org\/10.1345\/aph.1M241","journal-title":"Ann Pharmacother"},{"key":"4002_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2011.03.012","author":"JM Zuckerman","year":"2011","unstructured":"Zuckerman JM, Qamar F, Bono BR (2011) Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline). Med Clin North Am. https:\/\/doi.org\/10.1016\/j.mcna.2011.03.012","journal-title":"Med Clin North Am"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-021-04002-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-021-04002-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-021-04002-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T17:07:26Z","timestamp":1659114446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-021-04002-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,3]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4002"],"URL":"https:\/\/doi.org\/10.1007\/s00384-021-04002-9","relation":{},"ISSN":["0179-1958","1432-1262"],"issn-type":[{"value":"0179-1958","type":"print"},{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,3]]},"assertion":[{"value":"27 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the ethics committees at the participating sites. All patients signed informed consent before any study-related procedures were performed. The trial was carried out in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}